Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study

IF 3 3区 医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2024-10-04 DOI:10.1007/s00277-024-06017-y
Alexandre-Raphael Wery, Adriano Salaroli, Fabio Andreozzi, Marianne Paesmans, Laurent Dewispelaere, Pierre Heimann, Sebastian Wittnebel, Philippe Lewalle
{"title":"Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study","authors":"Alexandre-Raphael Wery,&nbsp;Adriano Salaroli,&nbsp;Fabio Andreozzi,&nbsp;Marianne Paesmans,&nbsp;Laurent Dewispelaere,&nbsp;Pierre Heimann,&nbsp;Sebastian Wittnebel,&nbsp;Philippe Lewalle","doi":"10.1007/s00277-024-06017-y","DOIUrl":null,"url":null,"abstract":"<div><p>Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques of measurable residual disease (MRD) have allowed us to refine their prognosis in two categories: MRD-positive and MRD-negative patients. We conducted a monocentric retrospective study (01/2000–12/2020) to assess the prognosis of pretransplant MRD status measured by multiparametric flow cytometry (MFC) and molecular biology assessed by PCR. 192 patients were included. The median follow-up period was 77 months. Among patients undergoing alloHSCT in CR, overall survival (median-OS: 130.6 vs. 16.0 months, <i>P</i> &lt; 0.001), disease-free survival (median-DFS: 109.6 vs. 7.1 months, <i>P</i> &lt; 0.001) and cumulative incidence of relapse (12-month CIR: 7.3% vs. 33.7%, <i>P</i> &lt; 0.0001) were significantly different between MRD-negative and MRD-positive patients. Patients with discordant intermethod results had intermediate DFS. MRD-negative patients according to molecular PCR-based techniques, WT1 overexpression and MFC had longer median-DFS, compared to MRD-positive patients (<i>P</i> = 0.001, <i>P</i> &lt; 0.001, <i>P</i> &lt; 0.001, respectively). Looking into subgroups, MRD-positive patients among the ELN2017 adverse-category (<i>P</i> &lt; 0.0001), myeloablative and reduced-intensity conditioning regimens (<i>P</i> &lt; 0.0001, <i>P</i> = 0.005), &lt; 60-year patients (<i>P</i> &lt; 0.001) and AML patients (<i>P</i> &lt; 0.001) were associated with lower DFS. This difference was not found in ≥ 60-year patients (<i>P</i> = 0.27) and MDS patients (<i>P</i> = 0.70). MRD-positive patients within the favorable/intermediate ELN2017 category trended toward lower DFS (<i>P</i> = 0.05). We confirmed that MRD status prior to alloHSCT is a strong prognostic factor for OS, DFS and CIR. Combining MFC and molecular-PCR techniques to assess MRD seems primordial as inter-method discordance can be consequential.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4671 - 4685"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-024-06017-y.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-024-06017-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques of measurable residual disease (MRD) have allowed us to refine their prognosis in two categories: MRD-positive and MRD-negative patients. We conducted a monocentric retrospective study (01/2000–12/2020) to assess the prognosis of pretransplant MRD status measured by multiparametric flow cytometry (MFC) and molecular biology assessed by PCR. 192 patients were included. The median follow-up period was 77 months. Among patients undergoing alloHSCT in CR, overall survival (median-OS: 130.6 vs. 16.0 months, P < 0.001), disease-free survival (median-DFS: 109.6 vs. 7.1 months, P < 0.001) and cumulative incidence of relapse (12-month CIR: 7.3% vs. 33.7%, P < 0.0001) were significantly different between MRD-negative and MRD-positive patients. Patients with discordant intermethod results had intermediate DFS. MRD-negative patients according to molecular PCR-based techniques, WT1 overexpression and MFC had longer median-DFS, compared to MRD-positive patients (P = 0.001, P < 0.001, P < 0.001, respectively). Looking into subgroups, MRD-positive patients among the ELN2017 adverse-category (P < 0.0001), myeloablative and reduced-intensity conditioning regimens (P < 0.0001, P = 0.005), < 60-year patients (P < 0.001) and AML patients (P < 0.001) were associated with lower DFS. This difference was not found in ≥ 60-year patients (P = 0.27) and MDS patients (P = 0.70). MRD-positive patients within the favorable/intermediate ELN2017 category trended toward lower DFS (P = 0.05). We confirmed that MRD status prior to alloHSCT is a strong prognostic factor for OS, DFS and CIR. Combining MFC and molecular-PCR techniques to assess MRD seems primordial as inter-method discordance can be consequential.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性髓性白血病和骨髓增生异常综合征异基因造血干细胞移植前的可测量残留疾病评估:一项为期20年的单中心研究。
接受异基因造血干细胞移植(alloHSCT)的急性髓性白血病(AML)或骨髓增生异常综合征(MDS)患者,在形态学上都处于完全缓解(CR)状态时,其生存结果可能会出现差异。可测量残留疾病(MRD)技术使我们能够将他们的预后分为两类:MRD阳性和MRD阴性患者。我们进行了一项单中心回顾性研究(2000 年 1 月至 2020 年 12 月),以评估通过多参数流式细胞术(MFC)测量的移植前 MRD 状态和通过 PCR 评估的分子生物学预后。共纳入 192 例患者。中位随访期为 77 个月。在 CR 期接受异体 HSCT 的患者中,总生存期(中位生存期:130.6 个月 vs. 16.0 个月,P
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
期刊最新文献
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists. Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Prognosis of patients with Hodgkin lymphoma and indeterminate response to PD-1 inhibitor therapy: considerations for application of LYRIC criteria in real clinical practice. Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1